GEV vs PFE: Which Is the Better Buy?
Side-by-side comparison of GE Vernova Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-24.
GE Vernova Inc. · Industrials
$951.82
+35.4% upside to fair value
Med Conviction
Grade B
High Quality
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
GEV has more upside to fair value
(+35.4%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
GEV |
PFE |
| Current Price |
$951.82 |
$27.64 |
| Fair Value Estimate |
$1,288.67 |
$30.94 |
| Upside to Fair Value |
+35.4%
|
+12.0%
|
| Market Cap |
$253.5B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
28.2x
|
17.4x
|
| Price / Sales |
6.1x
|
2.5x
|
| Price / FCF |
20.5x
|
14.3x
|
| Revenue Growth YoY |
+21.9%
|
+2.6%
|
| Gross Margin |
20.2%
|
71.3%
|
| Operating Margin |
4.4%
|
25.1%
|
| Return on Equity |
83.4%
|
4.9%
|
| Dividend Yield |
0.18% |
6.22% |
| FCF Yield |
4.88%
|
6.97%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
GE Vernova is an energy equipment and infrastructure enterprise spanning Power (gas, nuclear, hydro, steam), Wind (offshore and onshore turbines), and Electrification (grid, power conversion, solar and storage), with 78,000 employees and a Cambridge, Massachusetts headquarters. The business quality is high on the strength of an installed base that generates roughly 25% of the world's electricity,…
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
GEV |
PFE |
| Zone Low |
$966.50 |
$23.21 |
| Zone High |
$1,095.37 |
$26.30 |
| In Buy Zone? |
Yes
|
No
|